Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The recurrence and metastasis of peritoneum is always the lethal consequence for gastric
cancer patients, and there is no effective therapy until now. It has been reported by
Dr.Fujimoto that intraperitoneal chemotherapy plus hyperthermic therapy, which called
hyperthermic intraperitoneal chemotherapy (HIPEC), can eliminate and suppress the free cancer
cells and tiny metastasis in abdomen. Refer to the experience of systematic chemotherapy,
HIPEC with combination regimen would have a brighter prospect. In this study, the
investigators would use Oxaliplatin and paclitaxel sequent as HIPEC regimen. The safety and
overall survival would be observed and evaluated.